Double Blind Crossover Comparison of Diuretics in the Young
Primary Purpose
Low-Renin Hypertension
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Bendroflumethiazide 2.5mg - 5mg
Amiloride 20-40mg
Spironolactone 50-100mg
Frusemide 20-40mg
Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
Sponsored by

About this trial
This is an interventional treatment trial for Low-Renin Hypertension focused on measuring Hypertension, Low Renin
Eligibility Criteria
Inclusion Criteria:
- Aged 18-45
- male or female
- Hypertensive - 3 clinic SBP >=140mmHg; or 3 clinic DBP >=90mmHg; or ABPM or home BP >=130(SBP) or 85(DBP)
- 24hr Na+<160mmol/l
- EITHER {Plasma renin<=10mU/L (measured untreated, or whilst receiving only CCB+/-diuretic} + {Plasma renin <=40mU/L (measured on an ACEi or ARB, which approximately double s the plasma renin)} OR Plasma renin <5mU/L (measured untreated, or receiving any antihypertensive drug other than a beta-blocker
Exclusion Criteria:
- Documented history of gout
- Abnormal renal function (both elevated serum creatinine and reduced creatinine clearance
- SBP > 170mmHg or Diastolic >110mmHg despite treatment with permitted background treatment
Sites / Locations
- University of Cambridge - Addenbrookes HospitalRecruiting
Outcomes
Primary Outcome Measures
Difference in systolic blood pressure for subjects' best drug and second best drug.
Difference in plasma renin for subjects' best drug and second best drug.
Secondary Outcome Measures
Predictions of best drug
Full Information
NCT ID
NCT00429897
First Posted
January 31, 2007
Last Updated
January 31, 2007
Sponsor
University of Cambridge
Collaborators
British Heart Foundation
1. Study Identification
Unique Protocol Identification Number
NCT00429897
Brief Title
Double Blind Crossover Comparison of Diuretics in the Young
Official Title
Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
January 2007
Overall Recruitment Status
Unknown status
Study Start Date
August 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2007 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
University of Cambridge
Collaborators
British Heart Foundation
4. Oversight
5. Study Description
Brief Summary
The principle objective of the study is to determine whether low-renin (i.e. salt sensitive) hypertension at a young age is caused by the kidneys hanging onto too much salt as a result of an over active salt pump in the kidney.
The kidneys have four different salt pumps, and each is blocked by a different type of diuretic (salt losing tablet)If one out of the four is overactive, we would expect patients to respond much better to one diuretic than to the alternatives - rather than responding equally well to all available types of diuretic.
Detailed Description
Studies suggest that patients with low renin hypertension respond better to diuretics than other hypertensive drug groups. The aim of the study is to rotate patients through the four main diuretic groups and see if it is possible to identify the most effective diuretic for this group, as measured by a >=10mgHg decrease in Systolic blood pressure in one specific group a compared to the others.
As most caucasians with Low renin hypertension are older (>55), presentation with this type of hypertension at a younger age suggests the presence of substantial genetic variation in order to cause the atypical presentation. It is hoped that by identifying the best diuretic for these patients we will also be able to identify:
Whether the young low-renin hypertensives can be sub-classified according to their most effective diuretic;
Whether this sub-classification helps us to identify the genes and mutations responsible, since these are to expected to be in the so-called sodium channels (i.e. salt pumps)which the kidneys use to prevent salt being excreted in the urine.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low-Renin Hypertension
Keywords
Hypertension, Low Renin
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
30 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Bendroflumethiazide 2.5mg - 5mg
Intervention Type
Drug
Intervention Name(s)
Amiloride 20-40mg
Intervention Type
Drug
Intervention Name(s)
Spironolactone 50-100mg
Intervention Type
Drug
Intervention Name(s)
Frusemide 20-40mg
Intervention Type
Drug
Intervention Name(s)
Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
Primary Outcome Measure Information:
Title
Difference in systolic blood pressure for subjects' best drug and second best drug.
Title
Difference in plasma renin for subjects' best drug and second best drug.
Secondary Outcome Measure Information:
Title
Predictions of best drug
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 18-45
male or female
Hypertensive - 3 clinic SBP >=140mmHg; or 3 clinic DBP >=90mmHg; or ABPM or home BP >=130(SBP) or 85(DBP)
24hr Na+<160mmol/l
EITHER {Plasma renin<=10mU/L (measured untreated, or whilst receiving only CCB+/-diuretic} + {Plasma renin <=40mU/L (measured on an ACEi or ARB, which approximately double s the plasma renin)} OR Plasma renin <5mU/L (measured untreated, or receiving any antihypertensive drug other than a beta-blocker
Exclusion Criteria:
Documented history of gout
Abnormal renal function (both elevated serum creatinine and reduced creatinine clearance
SBP > 170mmHg or Diastolic >110mmHg despite treatment with permitted background treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Morris J Brown, Professor
Phone
01223 336743
Email
mjb14@medschl.cam.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Morris J Brown, Proffessor
Organizational Affiliation
Cambridge University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Cambridge - Addenbrookes Hospital
City
Cambridge
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Morris J Brown, Proffessor
Phone
01223 336743
Email
mjb14@medschl.cam.uk
First Name & Middle Initial & Last Name & Degree
Sue Hood, RGN - sister
First Name & Middle Initial & Last Name & Degree
Diane Picton, RGN- sister
First Name & Middle Initial & Last Name & Degree
Tim Burton, Phd, MRCP
12. IPD Sharing Statement
Learn more about this trial
Double Blind Crossover Comparison of Diuretics in the Young
We'll reach out to this number within 24 hrs